Spiriva Handihaler :
Spiriva Handihaler (tiotropium) is an inhaled medication from Boehringer Ingelheim Pharmaceuticals Inc. and jointly marketed by Boehringer and Pfizer Inc. in the U.S. It was approved in 2004 as a once-daily long-term treatment of bronchospasm linked with chronic obstructive pulmonary disease (COPD). Ipratropium is the generic name for Atrovent, which is also manufactured by Boehringer.
Recent Stuies Show Increased Risk Of Heart Problems Stroke And Death :
Recent studies have shown that patients on Spiriva or ipratropium had an increased risk of developing heart problems. Specifically, the study revealed a 53 percent higher risk for heart attacks, 80 percent for cardiovascular death and 46 percent for strokes.
This is not the first indication of concern with the Spiriva inhaler. In March 2008, the FDA raised concerns about the possible connection between side effects of Spiriva Handihaler and an increased risk of strokes.
View 9/24/08 JAMA Report >>>
View 9/16/2008 Annals of Internal Medicine Report >>>
Under no circumstances should you stop using Spiriva without consulting your physician first.
Spiriva News Archive >>>
If you or a loved one has suffered an adverse cardiac event, heart attack, stroke, or cardiac death while taking Spiriva or Atrovent for the treatment of COPD, or have other questions about potential Spiriva lawsuit, contact the Spiriva Attorneys of Ennis & Ennis, P.A. today for a free confidential case evaluation.
